Explore

ReutersReuters
Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

By Mariam Sunny Sept 14 (Reuters) - Eli Lilly on Monday said it has captured more than 30% of new patients in the U.S. market for oral obesity treatments, narrowing the early lead gained by Danish rival Novo Nordisk with its Wegovy pill.
Rapid ReadRapid Read
New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

New Study Links GLP-1 Weight Loss Drugs to Rare Brain Condition

A recent Israeli study has identified a potential link between GLP-1 weight loss and diabetes drugs and a rare, serious brain condition called Wernicke encephalopathy. The study, which reviewed U.S. Food and Drug Administration’s adverse event reports and related literature, found 15 cases of Wernicke encephalopathy between 2023 and 2024 in individuals taking these medications. Wernicke encephalopathy is a life-threatening neurological disorder caused by a severe deficiency of vitamin B1, which can lead to permanent memory loss and an inability to form new memories. Experts emphasize that this condition is rare, with only 15 cases identified out of millions of people using GLP-1 drugs. Most of the reported cases involved patients experiencing gastrointestinal side effects such as vomiting, diarrhea, and loss of appetite, which can lead to malnutrition and vitamin B1 deficiency. The majority of these cases were associated with semaglutide-based drugs like Ozempic and Wegovy, or tirzepatide GLP-1s such as Ze...
TheStreetTheStreet
Target is taking on Walmart with a major grocery move

Target is taking on Walmart with a major grocery move

The retailer hopes its latest partnership will help it carve out a distinct niche in the grocery market
Rapid ReadRapid Read
CVS Pharmacy Hours Vary by Location and Day, Impacting Prescription Access

CVS Pharmacy Hours Vary by Location and Day, Impacting Prescription Access

CVS Pharmacy operating hours, particularly for their pharmacy counters, exhibit significant variability across different locations and days of the week. While CVS retail stores often maintain longer hours, the pharmacy counters frequently operate on a different, often shorter, schedule. For instance, many CVS pharmacies open between 8 AM and 9 AM on weekdays and close around 8 PM or 9 PM. Weekend hours are typically shorter, with Saturday closures often around 6 PM or 7 PM, and Sunday hours commonly ranging from 10 AM or 11 AM to 5 PM or 6 PM. Furthermore, many CVS pharmacies implement a temporary closure for lunch, most commonly between 1:30 PM and 2:00 PM. This distinction between store and pharmacy hours is crucial, as a 24-hour CVS store does not necessarily imply a 24-hour pharmacy. Locations inside Target stores also tend to have different and often shorter pharmacy hours compared to standalone CVS pharmacies. Holiday schedules, such as Labor Day, Black Friday, and Christmas Day, can further reduce p...
Rapid ReadRapid Read
Corbus Pharmaceuticals Announces New Obesity Drug CRB-913 with Fewer Side Effects Than GLP-1s

Corbus Pharmaceuticals Announces New Obesity Drug CRB-913 with Fewer Side Effects Than GLP-1s

Corbus Pharmaceuticals has announced promising results for its new anti-obesity drug, CRB-913, claiming it can achieve similar weight loss to GLP-1s with fewer gastrointestinal side effects. In a recent drug trial, CRB-913 demonstrated a 5% weight loss at a 60mg dose after 12 weeks. The drug is a CB1 inverse agonist, which works by reducing the influence of the CB1 receptor, thereby decreasing hunger signals. This mechanism differs from GLP-1 receptor agonists, which mimic the GLP-1 hormone. Previous attempts to target CB1 receptors for obesity treatment faced challenges due to psychiatric side effects, but Corbus Pharmaceuticals states that CRB-913 has minimal brain penetration, with psychiatric adverse events broadly in line with those experienced by GLP-1 users.
TheStreetTheStreet
How a Costco partner's bankruptcy could benefit its biggest rival

How a Costco partner's bankruptcy could benefit its biggest rival

Reckitt does not need to win a vendor slot or navigate Costco's notoriously demanding supplier requirements. It is already approved, integrated, and selling.
ReutersReuters
Global bond yields hit 2008 highs, raising stakes for big borrowers

Global bond yields hit 2008 highs, raising stakes for big borrowers

By Tom Westbrook and Amanda Cooper SINGAPORE/LONDON, Sept 15 (Reuters) - Government borrowing costs hit their highest since the 2008 financial crisis on Tuesday, with 10-year U.S.
ReutersReuters
Trump's envoy meets Lukashenko for new talks on Belarus prisoner releases

Trump's envoy meets Lukashenko for new talks on Belarus prisoner releases

By Mark Trevelyan Sept 15 (Reuters) - U.S. presidential envoy John Coale met Belarusian President Alexander Lukashenko on Tuesday for their first talks in six months, as Washington pushes for the release of more political prisoners in return for easing sanctions.
TheStreetTheStreet
Morgan Stanley drops blunt verdict on Ozempic maker

Morgan Stanley drops blunt verdict on Ozempic maker

One date in the next decade is quietly doing all the work in Wall Street's newest bear case.
TrendlineTrendline
Retailers Integrate Digital Ad Screens to Boost Sales and Ad Revenue

Retailers Integrate Digital Ad Screens to Boost Sales and Ad Revenue

Retailers Integrate Digital Ad Screens to Boost Sales and Ad Revenue
TrendlineTrendline
Higher-Income U.S. Shoppers Increase Private Label Purchases, Reshaping Retail Strategies

Higher-Income U.S. Shoppers Increase Private Label Purchases, Reshaping Retail Strategies

Higher-Income U.S. Shoppers Increase Private Label Purchases, Reshaping Retail Strategies
TrendlineTrendline
Amazon Invests $230 Million in Whole Foods Employee Pay and Benefits Amidst Grocery Strategy Shift

Amazon Invests $230 Million in Whole Foods Employee Pay and Benefits Amidst Grocery Strategy Shift

Amazon Invests $230 Million in Whole Foods Employee Pay and Benefits Amidst Grocery Strategy Shift